Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Fondazione EMN Italy Onlus
- Target Recruit Count
- 84
- Registration Number
- NCT04096066
- Locations
- 🇮🇹
Ospedali Riuniti, Bergamo, Italy
🇮🇹AO di Padova, Padova, Italy
🇮🇹AO Bianchi Melacrino Morelli, Reggio Calabria, Italy
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 144
- Registration Number
- NCT04091126
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04084626
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1100
- Registration Number
- NCT04071457
- Locations
- 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Mount Carmel Health Center West, Columbus, Ohio, United States
🇺🇸Advocate Illinois Masonic Medical Center, Chicago, Illinois, United States
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients
- Conditions
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT04065789
- Locations
- 🇮🇱
Hematology Department Sourasky Medical Center, Tel Aviv, Israel
🇮🇱Soroka Medical Center, Be'er Sheva, Israel
🇮🇱Kaplan Medical center, Reẖovot, Israel
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
- Conditions
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Larysa Sanchez
- Target Recruit Count
- 18
- Registration Number
- NCT04052880
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
DNA Vaccination Against Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2022-03-02
- Target Recruit Count
- 12
- Registration Number
- NCT04049864
- Locations
- 🇧🇾
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk, Minsk Region, Belarus
Biomarker Guided Treatment in DLBCL
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT04025593
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 79
- Registration Number
- NCT04009109
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Northern Light Eastern Maine Medical Center, Bangor, Maine, United States
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
- Conditions
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Takeda
- Target Recruit Count
- 50
- Registration Number
- NCT03984097
- Locations
- 🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.